[1]
|
E. Brambilla, W. D. Travis, T. V. Colby, B. Corrin and Y. Shimosato, “The New World Health Organization Classification of Lung Tumors,” European Respiratory Journal, Vol. 18, No. 6, 2001, pp. 1059-1068.
doi:10.1183/09031936.01.00275301
|
[2]
|
M. Uehara, A. Watanabe, T. Nakajima, S. Nakashima, T. Higami and N. Inoue, “Pulmonary Pleomorphic Carcinoma; an Investigation of Thirteen Cases,” Kyobu Geka, Vol. 62, No. 2, 2009, pp. 89-93.
|
[3]
|
T. Yuki, T. Sakuma, C. Ohbayashi, M. Yohimura, N. Tsubota, Y. Okita, et al., “Pleomorphic Carcinoma of the Lung: A Surgical Outcome,” The Journal of Thoracic and Cardiovascular Surgery, Vol. 134, No. 2, 2007, pp. 399-404. doi:10.1016/j.jtcvs.2007.04.018
|
[4]
|
N. F. Fishback, W. D. Travis, C. A. Moran, D. G. Guinee Jr., W. F. McCarthy and M. N. Koss, “Pleomorphic (Spindle/Giant Cell) Carcinoma of the Lung. A Clinicopathologic Correlation of 78 Cases,” Cancer, Vol. 73, No. 12, 1994, pp. 2936-2945.
doi:10.1002/1097-0142(19940615)73:12<2936::AID-CNCR2820731210>3.0.CO;2-U
|
[5]
|
J. Y. Hong, M. K. Choi, J. E. Uhm, M. J. Park, J. Lee, Y. H. Park, et al., “The Role of Palliative Chemotherapy for Advanced Pulmonary Pleomorphic Carcinoma,” Medical Oncology, Vol. 26, No. 3, 2009, pp. 287-291.
doi:10.1007/s12032-008-9117-4
|
[6]
|
K. W. Lee, Y. J. Kim, J. H. Kim, S. M. Bang, J. H. Chung and J. S. Lee, “Two Consecutive Cases of Platinum-Refractory Pulmonary Pleomorphic Carcinoma that Showed Dramatic Responses to MAID (Mensa, Doxorubicin, Ifosfamide and Dacarbazine) Chemotherapy,” Japanese Journal of Clinical Oncology, Vol. 41, No. 3, 2011, pp. 430-433. doi:10.1093/jjco/hyq180
|